Aldo Peixoto, MD
Nephrology · New Haven, CTNPI 1073614921
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,880 of the $16,741 with a category attached, or 76.9%. Regeneron accounts for 64.4% of it on its own, with 5 other manufacturers making up the rest. Among nephrology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $440.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$11K
- Vifor Pharma, Inc.$4K
- Boehringer Ingelheim International GmbH$1K
- Travere Therapeutics, Inc.$193
- Bard Peripheral Vascular, Inc.$135
- Bayer$23
Across 135 payments — averaging $2567.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$125K
- Boehringer Ingelheim International GmbH$100K
- H. Lundbeck A S$72K
- Boehringer Ingelheim Pharma GmbH & Co.kg$49K
- Regeneron$958
What the payments were for
- Consulting fees$12,88077%
- Travel & lodging$2,94318%
- Food & beverage$7244%
- Education$1931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 17 | $10,773 |
| Vifor Pharma, Inc. | 8 | $4,200 |
| Boehringer Ingelheim International GmbH | 7 | $1,416 |
| Travere Therapeutics, Inc. | 3 | $193 |
| Bard Peripheral Vascular, Inc. | 2 | $135 |
| Bayer | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,741 in reported general payments places this provider in the 90th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 19 | $21,376 |
| Clonidine | 31 | $5,477 |
| Midodrine Hcl | 58 | $3,152 |
| Doxazosin Mesylate | 21 | $626 |
| Oxycodone Hcl | 11 | $477 |
| Alprazolam | 18 | $199 |
| Amlodipine Besylate | 30 | $131 |
| Labetalol Hcl | 14 | $104 |
| Losartan Potassium | 13 | $76 |
| Lisinopril | 17 | $40 |
| Clonidine Hcl | 19 | $19 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New Haven
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- Ladan GolestanehNew Haven$54K
- Ali Abu-AlfaNew Haven$16K
- Lloyd CantleyNew Haven$14K
- Sue ChangNew Haven$9K
- Margaret BiaNew Haven$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.